98%
921
2 minutes
20
Background: In patients with cardiac arrest who remain comatose after return of spontaneous circulation, seizures and other abnormalities on electroencephalogram (EEG) are common. Thus, guidelines recommend urgent initiation of EEG for the evaluation of seizures in this population. Point-of-care EEG systems, such as Ceribell™ Rapid Response EEG (Rapid-EEG), allow for prompt initiation of EEG monitoring, albeit through a reduced-channel montage. Rapid-EEG incorporates an automated seizure detection software (Clarity™) to measure seizure burden in real time and alert clinicians at the bedside when a high seizure burden, consistent with possible status epilepticus, is identified. External validation of Clarity is still needed. Our goal was to evaluate the real-world performance of Clarity for the detection of seizures and status epilepticus in a sample of patients with cardiac arrest.
Methods: This study was a retrospective review of Rapid-EEG recordings from all the patients who were admitted to the medical intensive care unit at Kent Hospital (Warwick, RI) between 6/1/2021 and 3/18/2022 for management after cardiac arrest and who underwent Rapid-EEG monitoring as part of their routine clinical care (n = 21). Board-certified epileptologists identified events that met criteria for seizures or status epilepticus, as per the 2021 American Clinical Neurophysiology Society's Standardized Critical Care EEG Terminology, and evaluated any seizure burden detections generated by Clarity.
Results: In this study, 4 of 21 patients with cardiac arrest (19.0%) who underwent Rapid-EEG monitoring had multiple electrographic seizures, and 2 of those patients (9.5%) had electrographic status epilepticus within the first 24 h of the study. None of these ictal abnormalities were detected by the Clarity seizure detection system. Clarity showed 0% seizure burden throughout the entirety of all four Rapid-EEG recordings, including the EEG pages that showed definite seizures or status epilepticus.
Conclusions: The presence of frequent electrographic seizures and/or status epilepticus can go undetected by Clarity. Timely and careful review of all raw Rapid-EEG recordings by a qualified human EEG reader is necessary to guide clinical care, regardless of Clarity seizure burden measurements.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12028-023-01681-w | DOI Listing |
J Child Neurol
September 2025
Department of Neurology, Nationwide Children's Hospital, Columbus, OH, USA.
This case report describes the use of doxazosin (Cardura) as a treatment for a patient with an autosomal dominant , single-nucleotide R398Q pathogenic variant, which has not previously been described in the literature. The patient has gain-of-function pathogenic genetic variant. Because of the patient's continued seizure burden with the use of traditional antiseizure medications and failed invasive antiseizure interventions, an oocyte cell line with the specific genetic variant was created to test efficacy of various medications.
View Article and Find Full Text PDFEpilepsy affects around 1% of the global population and often requires long-term treatment with antiseizure medications (ASMs). However, the current treatment strategy is based on clinical acumen and trial and error, resulting in only about 50% of patients remaining seizure-free for at least 12 months with first-line ASMs. Valproic acid (VPA) is a commonly prescribed first-line ASM, yet <50% of patients experience inadequate seizure control (ISC) or unacceptable adverse reactions (UARs), necessitating discontinuation.
View Article and Find Full Text PDFEur J Pediatr
September 2025
Child Neuropsychiatry Unit, University-Hospital Policlinico Umberto I, Istituto Di Neuropsichiatria Infantile "G. Bollea", Via Dei Sabelli 108, 00185, Rome, Italy.
Unlabelled: Neonatal status epilepticus (NSE) is associated with poor survival and adverse neurological outcomes. However, current definitions only partially account for the unique pathophysiology of the neonatal brain and the clinical context of acute symptomatic seizures. To address this gap, international efforts are underway to develop a more specific and context-appropriate definition for the neonatal period.
View Article and Find Full Text PDFCell Commun Signal
September 2025
CNR Institute of Biochemistry and Cell Biology, Monterotondo, Rome, 00015, Italy.
Background: Connexin (Cx) hemichannels (HCs) contribute to glioblastoma (GBM) progression by facilitating intercellular communication and releasing pro-tumorigenic molecules, including ATP and glutamate.
Methods: The efficacy of abEC1.1, a monoclonal antibody that inhibits Cx26, Cx30, and Cx32 HCs, was assessed in vitro by measuring invasion capability, dye and Ca uptake, glutamate and ATP release in patient-derived GBM cultures or organoids.
Epilepsy Behav
September 2025
Professor of Cultural and Social Anthropology, Dept. of Literature, Art and History, Chieti-Pescara University, Via dei Vestini 31, Chieti, Italy. Electronic address:
To live with epilepsy is to inhabit a space of perpetual uncertainty-between seizures, between wellness and risk, between life and the threat of sudden death. This editorial reflects on two recent contributions to Epilepsy & Behaviour addressing SUDEP risk communication and the redefinition of healing in epilepsy. Drawing on anthropological and phenomenological perspectives, the article explores how epilepsy disrupts categories of time, agency, and identity, and how biomedical approaches often fail to grasp the moral and relational dimensions of such disruption.
View Article and Find Full Text PDF